Zoetis says UK regulator approves Portela for cat osteoarthritis pain
ZTS•Dosage and portfolio context
The anti-NGF monoclonal antibody is dosed once every three months, extending Zoetis’ feline OA pain portfolio beyond monthly Solensia.
UK approval for Portela in cats
Zoetis says it won UK VMD clearance in Great Britain for Portela (relfovetmab) to treat osteoarthritis pain in cats.
